Building on the first Founders Longevity Forum held in June in London, at which Dr. Slawin brought our company out of five years of “stealth mode” to present our company publicly for the very first time, Dr. Slawin has now been invited back to attend this second event sponsored by Longevity.Technology and the National University of Singapore, to give an update on the amazing progress we’ve made since June in developing the world’s first gerotherapeutics aimed at an aging-specific target.
February 28th, Afternoon Session: Systemic Aging Reversal (Track 3):
Talk title: Novel Senolytic Peptides Reverse the Aging Phenotype In Naturally Aged Mice By Targeting Senescent Cells
